CClinicalTrials.gg
CompletedNCT03417804Updated Jul 6, 2021Results posted

Incidence of Postoperative Residual Neuromuscular Blockade in Portugal

An observational study in Residual Neuromuscular Blockade, Residual Paralysis, Post-Anesthesia and Observational Study, sponsored by Centro Hospitalar do Porto. Completed at 10 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-06.

Sponsored by Centro Hospitalar do Porto · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
366
Ages
18 Years and older
Sex
All
01

Study summary

This is an epidemiological multicenter, observational, prospective study, designed to determine the incidence of postoperative residual neuromuscular blockade - defined by a TOF (train-of-four) ratio \< 0.9 - at PACU arrival.

Subjects aged at least 18 years old (n=360) admitted for different types of elective surgical procedures requiring general anesthesia with neuromuscular blocking agents will be included.

Read the detailed description

This is a multicenter, observational/non-interventional study involving adult patients undergoing different types of elective surgical procedures requiring general anesthesia with neuromuscular blocking agents.

The study will have two periods:

  • Period 1 - Evaluation at PACU arrival.
  • Period 2 - Collection of hospital patient discharge data.

A total of 360 patients will be included from approximately 10 centers in Portugal, where the PACU is adjacent to the Operating Room (OR). Each center should recruit between 30 and 40 patients.

Each subject is considered to be enrolled in the study when the subject has provided written informed consent.

Enrollment will be stopped when approximately 360 patients are recruited.

A subject is considered to have completed the trial after all of the protocol specified activities are completed. A subject is considered to have discontinued after he/she has withdrawn consent or has been discontinued.

Overall, study start is when the first site is initiated and study ends at database lock.

During the routine preoperative anesthesia visit the patient will be asked to participate in the study. A description of the study will be provided to the patient by the investigator or qualified designee and any questions will be properly answered. If the patient agrees to participate in the study an informed consent form (ICF) will be signed.

Consent must be documented by the subject's dated signature or by the subject's legally acceptable representative's dated signature on a consent form along with the dated signature of the person conducting the consent discussion. A copy of the signed and dated consent form should be given to the subject before participation in the study.

The initial informed consent form, any subsequent revised written informed consent form and any written information provided to the subject must receive the IRB/ERC's (Institutional Review Board) ) approval/favorable opinion in advance of use. The subject or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subject's willingness to continue participation in the study.

All consented subjects will be given a unique patient number that will be used to identify the subject for all procedures. Each subject will be assigned only one patient number.

Immediately after patient arrival in the PACU and as soon as clinically adequate (basic monitoring and oxygen therapy in place) the anesthesiologist assigned to the PACU (who was not involved in the anesthetic procedure) will collect demographic data (gender, age, weight, height), vital signs (heart rate, blood pressure, oxygen saturation and temperature). Neuromuscular blockade (TOF Ratio) will be measured. Clinical history, co-morbidities, surgical diagnosis, ASA (American Society of Anesthesiology) classification and perioperative medication data (dosage and last administration time) will be collected as well.

As this is an observational study, intra-operative monitoring of neuromuscular blockade will not be mandatory by protocol and will be left at the discretion of the anesthesiologist as according to the clinical practice. Only information about whether this evaluation was performed or not, and if yes if it was used quantitative or qualitative methods, will be collected in the CRF (case report form) .

Neuromuscular blockade evaluation Neuromuscular blockade will be evaluated using a quantitative method. Three consecutive TOF stimulations will be applied. In case these 3 measures differ more than 20%, another sequence of 3 consecutive TOF measurements will be considered. If after the 2nd sequence the 3 consecutive TOF measurements still differ more than 20% between the maximum and the minimum the patient will be excluded.

This study will reflect real life clinical practice. The anesthetic technique in terms of drugs and type of monitoring used will be of entire responsibility of the anesthesiologist.

All study activities will be consistent with EU (European Union) directive 2001/20/EC section for non- interventional studies :

  • NMBAs (neuromuscular blocking agents) and reversal agents (as well as all drugs which will be used during the anesthesia) administration will be done in accordance with routine anesthesiology practice and labeling of these medicine products;
  • No further interventional means, methods or procedures, are scheduled for subjects, which would otherwise not be applied;
  • Furthermore, there will be no additional visits to the hospital or a mandatory visit schedule, deviating from daily clinical practice.
02

Conditions studied

  • Residual Neuromuscular Blockade
  • Residual Paralysis, Post-Anesthesia
  • Observational Study
  • Complication of Anesthesia
  • Neuromuscular Blockade
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients scheduled for surgery on 10 centers that accepted to participate in the study.

Inclusion criteria

  • 18 years of age or older;
  • Informed consent signed;
  • Admission for elective surgery;
  • Administration of non-depolarizing NMBAs during surgery

Exclusion criteria

Exclusion Criteria:

  • Admission for emergency surgery;
  • Reoperation on the same hospital admission;
  • More than 10 minutes elapsed between extubation and neuromuscular block monitoring at PACU
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
366 participants (actual)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Percentage of Patients With Postoperative Residual Neuromuscular Blockade

    Percentage of patients arriving PACU with a TOF ratio \< 0.9 measured as average of 3 consecutive TOF stimulations

    Time frame: No more than 10 minutes after operating room exit

Secondary outcomes

  1. Percentage of Patients With Severe Residual Postoperative Neuromuscular Blockade

    Percentage of patients with severe postoperative residual neuromuscular blockade defined by a TOF ratio \< 0.7

    Time frame: no more than 10 minutes after operating room exit

  2. Association of Postoperative Residual Blockade and the Use of Reversal Agents

    Association of postoperative residual blockade and the use of reversal agents (neostigmine, sugammadex or none)

    Time frame: no more than 10 minutes after operating room exit

  3. Association of Postoperative Residual Blockade and the Use of Intra-operative Monitoring of Neuromuscular Blockade

    To evaluate the association of postoperative residual blockade and the use of intra-operative monitoring of neuromuscular blockade

    Time frame: no more than 10 minutes after operating room exit

Other outcomes

  1. Association of Postoperative Residual Blockade and ASA Status

    To evaluate the association of postoperative residual blockade with co- morbidities and ASA status

    Time frame: no more than 10 minutes after operating room exit

06

Results

Posted Jul 6, 2021
Limitations and caveats
Due to its observational nature, it was not possible to standardize practices between centres. A convenience sample was used (patients were included when investigators were scheduled to PACU), what may have biased the study sample

Participant flow

Patients \> 18 years old submitted to surgery under general anesthesia with the use of non-depolarizing neuromuscular blocking agents from 10 public Portuguese hospitals

Participant flow — Overall Study
MilestonePatients Proposed for Elective Surgical Procedures
Started366
Completed366
Not completed0

Outcome measures

PrimaryPercentage of Patients With Postoperative Residual Neuromuscular Blockade

Percentage of patients arriving PACU with a TOF ratio \< 0.9 measured as average of 3 consecutive TOF stimulations

Time frame:
No more than 10 minutes after operating room exit
Reported as:
Count of participants · Participants
Percentage of Patients With Postoperative Residual Neuromuscular Blockade
ParticipantsPatients Proposed for Elective Surgical Procedures
Percentage of Patients With Postoperative Residual Neuromuscular Blockade20
SecondaryPercentage of Patients With Severe Residual Postoperative Neuromuscular Blockade

Percentage of patients with severe postoperative residual neuromuscular blockade defined by a TOF ratio \< 0.7

Time frame:
no more than 10 minutes after operating room exit
Reported as:
Count of participants · Participants
Percentage of Patients With Severe Residual Postoperative Neuromuscular Blockade
ParticipantsPatients Proposed for Elective Surgical Procedures
Percentage of Patients With Severe Residual Postoperative Neuromuscular Blockade2
SecondaryAssociation of Postoperative Residual Blockade and the Use of Reversal Agents

Association of postoperative residual blockade and the use of reversal agents (neostigmine, sugammadex or none)

Time frame:
no more than 10 minutes after operating room exit

Results for this outcome have not been posted.

SecondaryAssociation of Postoperative Residual Blockade and the Use of Intra-operative Monitoring of Neuromuscular Blockade

To evaluate the association of postoperative residual blockade and the use of intra-operative monitoring of neuromuscular blockade

Time frame:
no more than 10 minutes after operating room exit

Results for this outcome have not been posted.

Other pre-specifiedAssociation of Postoperative Residual Blockade and ASA Status

To evaluate the association of postoperative residual blockade with co- morbidities and ASA status

Time frame:
no more than 10 minutes after operating room exit

Results for this outcome have not been posted.

Adverse events

Collected over 1 day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Proposed for Elective Surgical Procedures0/366 (0%)2/366 (0.5%)10/366 (2.7%)
Most frequent serious events
Most frequent serious events
EventPatients Proposed for Elective Surgical Procedures
Pulmunary thromboembolismRespiratory, thoracic and mediastinal disorders1/366
Severe residual neuromuscular blockadeMusculoskeletal and connective tissue disorders1/366
Most frequent other events
Most frequent other events
EventPatients Proposed for Elective Surgical Procedures
HypoxemiaRespiratory, thoracic and mediastinal disorders9/366
Sore throatGeneral disorders1/366

Baseline characteristics

Age, Continuous
Age, Continuous(years)Patients Proposed for Elective Surgical Procedures
Median59 (48 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Patients Proposed for Elective Surgical Procedures
Female207
Male159
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Patients Proposed for Elective Surgical Procedures
Region of Enrollment
Region of Enrollment(participants)Patients Proposed for Elective Surgical Procedures
Portugal366
07

Study locations

10 sites
  • Hospital Prof. Fernando Fonseca, EPE
    Amadora, 2720-276, Portugal
  • Centro Hospitalar Baixo Vouga
    Aveiro, Portugal
  • Centro Hospitalar Universitário de Coimbra
    Coimbra, Portugal
  • Centro Hospitalar Lisboa Norte
    Lisboa, Portugal
  • Hospital Pedro Hispano
    Matosinhos, Portugal
  • Centro Hospitalar Tamega Sousa
    Penafiel, Portugal
  • Centro Hospitalar do Porto
    Porto, Portugal
  • Centro Hospitalar S. João
    Porto, Portugal
  • Centro Hospitalar Vila Nova Gaia/Espinho
    Vila Nova De Gaia, Portugal
  • Centro Hospitalar Tondela Viseu
    Viseu, Portugal
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Sep 15, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Registry details

Key details

Study ID
NCT03417804
Lead sponsor
Centro Hospitalar do Porto
Responsible party
Simao Esteves (MD, Centro Hospitalar do Porto) — Principal investigator
First posted
Jan 31, 2018
Start date
Jun 18, 2018
Primary completion
Jul 16, 2019
Completion
Nov 1, 2019
Results posted
Jul 6, 2021
Last update
Jul 6, 2021

Study contacts

Simao Esteves, MD
principal investigator · Centro Hospitalar do Porto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion